HighMark Wealth Management’s X4 Pharmaceuticals XFOR Stock Holding History

HighMark Wealth Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28	Hold	6	–	–	﹤0.01%	557
2026 Q1	$24	Hold	6	–	–	﹤0.01%	549
2025 Q4	$24	Hold	6	–	–	﹤0.01%	581
2025 Q3	$21	Hold	6	–	–	﹤0.01%	604
2025 Q2	$11	Hold	6	–	–	﹤0.01%	612
2025 Q1	$43	Hold	6	–	–	﹤0.01%	567
2024 Q4	$132	Hold	6	–	–	﹤0.01%	557
2024 Q3	$120	Hold	6	–	–	﹤0.01%	576
2024 Q2	$104	Buy	+6	New	+$196	﹤0.01%	574

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HighMark Wealth Management's XFOR Position: Q2 2026 in Review

HighMark Wealth Management held its X4 Pharmaceuticals (XFOR) position steady in Q2 2026 at 6 shares worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #557.

HighMark Wealth Management first reported a position in XFOR in Q2 2024 and has held it in 9 quarters since. The position peaked at $132 in Q4 2024. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

HighMark Wealth Management held 6 shares of X4 Pharmaceuticals worth $28 as of Q2 2026.
HighMark Wealth Management left its X4 Pharmaceuticals share count unchanged in Q2 2026.
X4 Pharmaceuticals made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #557 holding.
HighMark Wealth Management first reported a position in X4 Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
HighMark Wealth Management's X4 Pharmaceuticals position peaked at $132 in Q4 2024.
89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.